In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
July 15th, 2008 | 30 | Yes |
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 2.57 | 6.69 | -16.04 | 3 | 7 | 0 | 103 | 398.422 | 4 | ↓ |
Mid Mid (pH 6-8) | 2.57 | 7.18 | -42.22 | 4 | 7 | 1 | 104 | 399.43 | 4 | ↓ |
Lo Low (pH 4.5-6) | 2.57 | 6.91 | -39.83 | 4 | 7 | 1 | 104 | 399.43 | 4 | ↓ |
Lo Low (pH 4.5-6) | 2.57 | 7.28 | -103.07 | 5 | 7 | 2 | 106 | 400.438 | 4 | ↓ |
Lo Low (pH 4.5-6) | 2.57 | 7.09 | -41.63 | 4 | 7 | 1 | 104 | 399.43 | 4 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
Purity | 95% | Fluorochem |
PUBCHEM_PATENT_ID | WO2000061576A1 | IBM Patent Data |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
KC1D-1-E | Casein Kinase I Delta (cluster #1 Of 1), Eukaryotic | Eukaryotes | 300 | 0.30 | Binding ≤ 10μM |
KPCD1-1-E | Protein Kinase C Mu (cluster #1 Of 3), Eukaryotic | Eukaryotes | 9100 | 0.24 | Binding ≤ 10μM |
MK14-1-E | MAP Kinase P38 Alpha (cluster #1 Of 3), Eukaryotic | Eukaryotes | 5800 | 0.24 | Binding ≤ 10μM |
TGFR1-1-E | TGF-beta Receptor Type I (cluster #1 Of 1), Eukaryotic | Eukaryotes | 500 | 0.29 | Binding ≤ 10μM |
CSK2A-1-O | Casein Kinase II Subunit Alpha (cluster #1 Of 1), Other | Other | 200 | 0.31 | Binding ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
KC1D_HUMAN | P48730 | Casein Kinase I Delta, Human | 300 | 0.30 | Binding ≤ 1μM |
KC1D_RAT | Q06486 | Casein Kinase I Delta, Rat | 300 | 0.30 | Binding ≤ 1μM |
CSK2A_SCHPO | P40231 | Casein Kinase II Subunit Alpha, Schpo | 200 | 0.31 | Binding ≤ 1μM |
TGFR1_HUMAN | P36897 | TGF-beta Receptor Type I, Human | 500 | 0.29 | Binding ≤ 1μM |
KC1D_RAT | Q06486 | Casein Kinase I Delta, Rat | 300 | 0.30 | Binding ≤ 10μM |
KC1D_HUMAN | P48730 | Casein Kinase I Delta, Human | 300 | 0.30 | Binding ≤ 10μM |
CSK2A_SCHPO | P40231 | Casein Kinase II Subunit Alpha, Schpo | 200 | 0.31 | Binding ≤ 10μM |
MK14_HUMAN | Q16539 | MAP Kinase P38 Alpha, Human | 5800 | 0.24 | Binding ≤ 10μM |
KPCD1_HUMAN | Q15139 | Protein Kinase C Mu, Human | 9100 | 0.24 | Binding ≤ 10μM |
TGFR1_HUMAN | P36897 | TGF-beta Receptor Type I, Human | 500 | 0.29 | Binding ≤ 10μM |
Description | Species |
---|---|
activated TAK1 mediates p38 MAPK activation | |
Activation of PPARGC1A (PGC-1alpha) by phosphorylation | |
Activation of the AP-1 family of transcription factors | |
ADP signalling through P2Y purinoceptor 1 | |
CDO in myogenesis | |
Circadian Clock | |
Condensation of Prometaphase Chromosomes | |
Downregulation of TGF-beta receptor signaling | |
DSCAM interactions | |
ERK/MAPK targets | |
KSRP destabilizes mRNA | |
Loss of Nlp from mitotic centrosomes | |
Loss of proteins required for interphase microtubule organization from the ce | |
NOD1/2 Signaling Pathway | |
Oxidative Stress Induced Senescence | |
p38MAPK events | |
Platelet sensitization by LDL | |
Recruitment of mitotic centrosome proteins and complexes | |
Regulation of PLK1 Activity at G2/M Transition | |
SMAD2/3 MH2 Domain Mutants in Cancer | |
SMAD2/3 Phosphorylation Motif Mutants in Cancer | |
Sphingolipid de novo biosynthesis | |
TGF-beta receptor signaling activates SMADs | |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | |
TGFBR1 KD Mutants in Cancer | |
TGFBR1 LBD Mutants in Cancer | |
TGFBR2 Kinase Domain Mutants in Cancer | |
VEGFA-VEGFR2 Pathway |